OBJECTIVES: Recent data indicate that an elevated serum level of high-sensitivity C-reactive protein (hs-CRP) predicts the risk of recurrent coronary events. This study assessed the effects of baseline and 1 month F/U hs-CRP levels on the prediction of 2 year clinical outcomes in patients with successful drug-eluting stents (DES) implantation. METHOD: This was based on a retrospective analysis of SNUH DES registry. We analyzed 780 consecutive patients, among whom 71 patients had both baseline and 1 month F/U hs-CRP levels. Major adverse cardiocerebrovascular events (MACCE) including death, myocardial infarction, cerebrovascular event, and repeated intervention of the stented vessel occurring within 9 month F/U were defined as early MACCE and those occurring after 9 month F/U as late MACCE. RESULT: Baseline hs-CRP levels were not different among no, early, and late MACCE groups (P= .817). However, 1 month F/U hs-CRP levels were significantly higher in early MACCE group compared with no and late MACCE groups (P= .002). The gap between baseline and 1 month F/U hs-CRP levels were not different among those 3 groups (P= .884). On multivariate analysis, 1 month F/U hs-CRP levels emerged as an independent variable, although not statistically significant. CONCLUSION: Transient increases of hs-CRP levels are induced by coronary stenting and may be associated with adverse clinical outcomes. 1 month F/U hs-CRP levels may be a single useful predictor of early adverse clinical outcomes in patient undergoing coronary stenting in DES era.